Premium
Costes del manejo del paciente con Leishmaniasis Visceral en Muzaffarpur, India
Author(s) -
Meheus Filip,
Boelaert Marleen,
Baltussen Rob,
Sundar Shyam
Publication year - 2006
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2006.01732.x
Subject(s) - indirect costs , psychological intervention , total cost , medicine , visceral leishmaniasis , economic cost , public health , cost–benefit analysis , health care , environmental health , business , leishmaniasis , economic growth , economics , immunology , nursing , ecology , accounting , neoclassical economics , biology
Summary Objectives To identify and quantify the direct and indirect economic cost of treatment for visceral leishmaniasis (VL) with conventional Amphotericin B deoxycholate, currently the first‐line treatment in Muzaffarpur. Methods Costs of patient management for VL were estimated from a societal and household perspective by means of a questionnaire designed for this study, interviews and financial reports. Results The total cost of care per episode of VL from the societal perspective was estimated at US$355, equivalent to 58% of annual household income. The largest cost category was medical costs (55%), followed by indirect costs (36%) and non‐medical costs (9%). The cost from the household perspective was equivalent to US$217. The largest cost category was indirect costs (59%), followed by medical costs (27%) and non‐medical costs (15%). Loss of income because of illness and hospitalization and expenses for drugs were the largest cost components. Conclusions The economic costs related to VL are substantial, both to society and the patient. Public health authorities in Bihar should focus on policies that detect VL in the early stage and implement interventions that minimize the burden to households affected by VL.